Regulatory statusDistinct from approved mecasermin
What you need to know in 20 seconds
What is it?
Modified IGF-1 analogue protein/peptide
Research focus
Growth-factor and muscle/tissue biology research
Human evidence
No verified therapeutic human trial programme for Long R3 IGF-1 itself was identified. Published evidence is dominated by biochemical/preclinical work and product-identity analysis.
Regulatory status
Long R3 IGF-1 is not the same product as FDA-approved mecasermin (recombinant human IGF-1).
Main limitations
Human efficacy, dosing, pharmacokinetics, long-term safety or performance/recovery benefit.
Safety
Systemic IGF-1 receptor activation can affect glucose and tissue growth; long-term safety of LR3 in humans is unknown.
i
No verified therapeutic human trial programme for Long R3 IGF-1 itself was identified. Published evidence is dominated by biochemical/preclinical work and product-identity analysis.
What the evidence actually supports
✓Emphasize both absence of therapeutic human evidence and documented black-market quality concerns.
✓Evidence-gap record plus product-quality warning.
What is not established / key limitations
×No approved therapeutic use; black-market product analyses found oxidized/low-quality forms.
×No validated human therapeutic regimen or efficacy outcome identified.
Selected study & evidence records
LongR3-IGF-I anti-doping analytical study and product-quality evidence
2021 · Analytical / anti-doping study
Authors state LongR3-IGF-I and related analogues were never approved for human use; black-market products showed oxidized/low-quality forms.
Systemic IGF-1 receptor activation can affect glucose and tissue growth; long-term safety of LR3 in humans is unknown.
Systemic IGF-1 receptor activation can affect glucose and tissue growth. Black-market product analyses have found oxidized or low-quality forms.
Technical details
Mechanism / biologyIGF-1 receptor agonism with modifications designed to alter binding-protein interactions and prolong activity.
Route / formulation boundaryDo not transfer clinical evidence for native IGF-1 or mecasermin to Long R3 IGF-1.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusDosing research conclusion recorded. No verified therapeutic human dosing regimen identified; anti-doping literature documents the analogue but states IGF-I analogues such as Long R3 IGF-I were never approved for human use.
Identifiers & alternate namesIGF-1 LR3 · LR3 · Long R3 · Long R3 IGF-I
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
